Promoter holding
64.27%
AP
Aimil Pharmaceuticals(India) Limited - Due diligence report
A 360° intelligence report on Aimil Pharmaceuticals(India) Limited: trust score, financial health, credit view, compliance, directors, growt…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Aimil Pharmaceuticals(India) Limited — 360° Intelligence Report
Generated from MCA filings & public records69/100
Trust Score
Moderate
Aimil Pharmaceuticals(India) Limited is assessed as Moderate with a Trust Score of 69/100. Aimil Pharmaceuticals(India) Limited is an active public limited indian non-government company incorporated in 1984, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 19 Jul 2026 from the latest processed filings. Aimil Pharmaceuticals(India) Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
69/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
31/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 7 open (94.34 cr) · 14 satisfied (24.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 11 | 48.0 cr |
| H P Financial Corporation | 1 | 48.0 cr |
| Syndicate Bank | 1 | 48.0 cr |
| Punjab National Bank | 6 | 48.0 cr |
| Tata Capital Financial Services Limited | 1 | 48.0 cr |
| The Bank Of Rajasthan Ltd. | 1 | 48.0 cr |
Compliance Score: 31/100 Caution Indicated
- Company status is Active as per MCA.
- Last balance sheet is for Mar 2023 - filings overdue.
- Flagged by authority: EPFO.
- Litigation present in 2 court forum(s).
- 20 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| IKSHIT SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Sanchit Sharma | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KANWAL KUMAR SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PANKAJ MARWAHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SATYA PRAKASH SHRIVASTAVA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANJULA SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: KANWAL KUMAR SHARMA (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
Operating for 41+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Statutory filings appear overdue.
Compliance score is weak (31/100).
7 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence57/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment46/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 7 open charge(s) of 94.34 cr already registered.
- Compliance gaps should be priced into terms.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events22 Apr 2025
Charge satisfied
Others
Charge satisfied
Punjab National Bank
12 Feb 2025
Director appointed
Sanchit Sharma (Additional Director)
15 Jan 2025
Charge satisfied
Others
Charge satisfied
Punjab National Bank
30 Sep 2023
Last AGM held
Annual general meeting
08 Sep 2023
Charge created
Tata Capital Financial Services Limited - 1.75 cr
31 Mar 2023
Latest balance sheet
Filed with ROC
29 Oct 2021
Charge created
Others - 13.75 cr
08 Oct 2021
Charge created
Others - 34.75 Lakh
23 Jun 2021
Charge created
Others - 1.00 cr
31 Dec 2020
Director ceased
IKSHIT SHARMA
21 Nov 2019
Director appointed
IKSHIT SHARMA (Director)
14 Oct 2019
Charge created
Others - 83.51 Lakh
24 May 2019
Director ceased
SUBHASH SHARMA
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
6 active director(s) / partner(s); board looks stable and experienced.
20 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Rsh Global | U20237WB2005PTC103808 | Kolkata, West Bengal, India |
| Scott Edil Pharmacia Limited | U24232CH2003PLC025699 | Chandigarh, Chandigarh, India |
| Satyesh Brinechem | U24100GJ2014PTC078780 | Ahmedabad, Gujarat, India |
| Goldstab Organics Private Limited | U24110MH1997PTC108843 | Mumbai, Maharashtra, India |
| Goldstone Cements | U26940ML2007PLC008298 | Khliehriat, Meghalaya, India |
| Dasami Lab Private Limited | U24240TG2015PTC099918 | Chityal, Telangana, India |
| Gujarat Polysol Chemicals Limited | U24231GJ1989PLC012892 | Vapi, Gujarat, India |
| H.B. Fuller India Adhesives Private Limited | U74999PN2008PTC158367 | Shirwal, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Aimil Pharmaceuticals(India) Limited before audits and certifications: compliance score 31/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Aimil Pharmaceuticals(India) Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Aimil Pharmaceuticals(India) Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 69/100, distress signals and MSME payment-delay disclosures - know whether Aimil Pharmaceuticals(India) Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Aimil Pharmaceuticals(India) Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Aimil Pharmaceuticals(India) Limited an active company?
Aimil Pharmaceuticals(India) Limited has MCA status “Active” with a compliance score of 31/100 (Caution Indicated).
Is Aimil Pharmaceuticals(India) Limited financially healthy?
Aimil Pharmaceuticals(India) Limited has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Aimil Pharmaceuticals(India) Limited?
Its overall Trust Score is 69/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Aimil Pharmaceuticals(India) Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.
Does Aimil Pharmaceuticals(India) Limited have loans or charges against its assets?
7 open charge(s) are registered against its assets, and 14 earlier charge(s) stand satisfied.
Is Aimil Pharmaceuticals(India) Limited up to date with its ROC filings?
Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 31/100 (Caution Indicated).
Is it risky to lend to Aimil Pharmaceuticals(India) Limited?
Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
